is known ir-HBV (100 mg daily) or placebo in these trials are shown in the following tables. Table 7. Histologic Response at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Improvement was defined as a greater than or equal to 2-point decrease in the Knodell Histologic Activity Index (HAI) at Week 52 compared with pretreatment HAI. Subjects with missing data at baseline were excluded. Assessment Trial 1 Trial 2 Trial 3 EPIVIR - HBV (n = 62) Placebo (n = 63) EPIVIR - HBV (n = 131) Placebo (n = 68) EPIVIR - HBV (n = 110) Placebo (n = 54) Improvement a 55% 25% 56% 26% 56% 26% No Improvement 27% 59% 36% 62% 25% 54% Missing Data 18% 16% 8% 12% 19% 20% Table 8. HBeAg Seroconverters a at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Three-component seroconversion was defined as Week 52 values showing loss of HBeAg minimize

is known ir-HBV (100 mg daily) or placebo in these trials are shown in the following tables. Table 7. Histologic Response at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Improvement was defined as a greater than or equal to 2-point decrease in the Knodell Histologic Activity Index (HAI) at Week 52 compared with pretreatment HAI. Subjects with missing data at baseline were excluded. Assessment Trial 1 Trial 2 Trial 3 EPIVIR - HBV (n = 62) Placebo (n = 63) EPIVIR - HBV (n = 131) Placebo (n = 68) EPIVIR - HBV (n = 110) Placebo (n = 54) Improvement a 55% 25% 56% 26% 56% 26% No Improvement 27% 59% 36% 62% 25% 54% Missing Data 18% 16% 8% 12% 19% 20% Table 8. HBeAg Seroconverters a at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Three-component seroconversion was defined as Week 52 values showing loss of HBeAg minimize

December 21, 2016
unfavourable ir-HBV (100 mg daily) or placebo in these trials are shown in the following tables. Table 7. Histologic Response at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Improvement was defined as a greater than or equal to 2-point decrease in the Knodell Histologic Activity Index (HAI) at Week 52 compared with pretreatment HAI. Subjects with missing data at baseline were excluded. Assessment Trial 1 Trial 2 Trial 3 EPIVIR - HBV (n = 62) Placebo (n = 63) EPIVIR - HBV (n = 131) Placebo (n = 68) EPIVIR - HBV (n = 110) Placebo (n = 54) Improvement a 55% 25% 56% 26% 56% 26% No Improvement 27% 59% 36% 62% 25% 54% Missing Data 18% 16% 8% 12% 19% 20% Table 8. HBeAg Seroconverters a at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Three-component seroconversion was defined as Week 52 values showing loss of HBeAg remains
 
Photo :ir-HBV (100 mg daily) or placebo in these trials are shown in the following tables. Table 7. Histologic Response at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Improvement was defined as a greater than or equal to 2-point decrease in the Knodell Histologic Activity Index (HAI) at Week 52 compared with pretreatment HAI. Subjects with missing data at baseline were excluded. Assessment Trial 1 Trial 2 Trial 3 EPIVIR - HBV (n = 62) Placebo (n = 63) EPIVIR - HBV (n = 131) Placebo (n = 68) EPIVIR - HBV (n = 110) Placebo (n = 54) Improvement a 55% 25% 56% 26% 56% 26% No Improvement 27% 59% 36% 62% 25% 54% Missing Data 18% 16% 8% 12% 19% 20% Table 8. HBeAg Seroconverters a at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Three-component seroconversion was defined as Week 52 values showing loss of HBeAg

place of business gain of HBeAb look


without notice ir-HBV (100 mg daily) or placebo in these trials are shown in the following tables. Table 7. Histologic Response at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Improvement was defined as a greater than or equal to 2-point decrease in the Knodell Histologic Activity Index (HAI) at Week 52 compared with pretreatment HAI. Subjects with missing data at baseline were excluded. Assessment Trial 1 Trial 2 Trial 3 EPIVIR - HBV (n = 62) Placebo (n = 63) EPIVIR - HBV (n = 131) Placebo (n = 68) EPIVIR - HBV (n = 110) Placebo (n = 54) Improvement a 55% 25% 56% 26% 56% 26% No Improvement 27% 59% 36% 62% 25% 54% Missing Data 18% 16% 8% 12% 19% 20% Table 8. HBeAg Seroconverters a at Week 52 among Adult Subjects Receiving Epivir-HBV 100 mg Once Daily or Placebo a Three-component seroconversion was defined as Week 52 values showing loss of HBeAg in recent times


EmoticonEmoticon

Subscribe to: Post Comments (Atom)